Louis J Denis
Overview
Explore the profile of Louis J Denis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
2874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Remmers S, Bangma C, Godtman R, Carlsson S, Auvinen A, Tammela T, et al.
Eur Urol
. 2023 Apr;
84(5):503-509.
PMID: 37088597
Background: The European Association of Urology guidelines recommend a risk-based strategy for prostate cancer screening based on the first prostate-specific antigen (PSA) level and age. Objective: To analyze the impact...
2.
Smith R, Zammit D, Damle N, Usansky H, Reddy S, Lin J, et al.
Mol Cancer Ther
. 2021 May;
20(8):1327-1337.
PMID: 34045226
The 5T4 oncofetal antigen (trophoblast glycoprotein) is expressed in a wide range of malignant tumors but shows very limited expression in normal adult tissues. ASN004 is a 5T4-targeted antibody-drug conjugate...
3.
Hugosson J, Roobol M, Mansson M, Tammela T, Zappa M, Nelen V, et al.
Eur Urol
. 2019 Mar;
76(1):43-51.
PMID: 30824296
Background: The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality. Objective: To determine whether PSA screening...
4.
Auvinen A, Moss S, Tammela T, Taari K, Roobol M, Schroder F, et al.
Clin Cancer Res
. 2015 Aug;
22(1):243-9.
PMID: 26289069
Purpose: The balance of benefits and harms in prostate cancer screening has not been sufficiently characterized. We related indicators of mortality reduction and overdetection by center within the European Randomized...
5.
Morgans A, van Bommel A, Stowell C, Abrahm J, Basch E, Bekelman J, et al.
Eur Urol
. 2015 Jul;
68(5):891-8.
PMID: 26129856
Background: There are no universally monitored outcomes relevant to men with advanced prostate cancer, making it challenging to compare health outcomes between populations. Objective: We sought to develop a standard...
6.
Buzzoni C, Auvinen A, Roobol M, Carlsson S, Moss S, Puliti D, et al.
Eur Urol
. 2015 Mar;
68(5):885-90.
PMID: 25791513
Background: The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer (PCa) mortality and a 1.6-fold increase in PCa incidence with prostate-specific...
7.
Schroder F, Hugosson J, Roobol M, Tammela T, Zappa M, Nelen V, et al.
Lancet
. 2014 Aug;
384(9959):2027-35.
PMID: 25108889
Background: The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is...
8.
Bangma C, Bul M, van der Kwast T, Pickles T, Korfage I, Hoeks C, et al.
Crit Rev Oncol Hematol
. 2012 Aug;
85(3):295-302.
PMID: 22878262
Active surveillance (AS) is an important management strategy for men diagnosed with low-risk prostate cancer (PCa). The need for AS is increasing due to the awareness that many PCa are...
9.
Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V, et al.
N Engl J Med
. 2012 Mar;
366(11):981-90.
PMID: 22417251
Background: Several trials evaluating the effect of prostate-specific antigen (PSA) testing on prostate-cancer mortality have shown conflicting results. We updated prostate-cancer mortality in the European Randomized Study of Screening for...
10.
Denis L, Roobol M, Dourcy-Belle-Rose B
Acta Oncol
. 2011 May;
50 Suppl 1:148-54.
PMID: 21604956
The democratization of civil society and the development of modern medicine changed the sacrosanct doctor-patient relationship to a doctor-partner dialogue. Values and respect were lost in the process where common...